Mithi Thaya

Investor & Operator

📍 United States🔄 Updated September 2026💼 3 investments📅 5 years investing🗓 Last invested Aug 2024
VC🌍 United States
3
Total investments
1
Early stage
0
Mid stage
1
Late stage
5y
Years active

Portfolio

3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor & Board of Advisors
Aug 2024
HerculesAI is a generative AI company that brings the power of large language models inside the security perimeter of enterprises. Its powerful operating and orchestration platform, Hercules, enables enterprises to quickly create, deploy, and run generative AI apps without compromising security standards. These apps can augment knowledge workers in any domain, resulting in higher revenue, improved profitability, and enhanced worker satisfaction. To learn more visit https://www.hercules.ai
Investor & Board of Advisors
Mar 2023
Lindus is an Accountable Research Organization, engineered to give biotech and pharmaceutical sponsors confidence and control to generate clinical data on time and on budget. In the last 3 years, Lindus has executed over 45 full-scope trials across cardiometabolic, respiratory, psychiatry, dermatology, womens health, and diagnostics. Behind each study is an integrated model spanning feasibility, central enrollment infrastructure, and flexible site models. Trials run on Citrus™, an AI-native trial operating system, and are governed by performance-based contracts with milestone-based payments. 82% of Lindus executed trials completed enrollment on or ahead of our proposed timeline. The company is backed by Dr. Bob Langer, Peter Thiel, and Dr. Tim Garnett.
Investor
2021
Homey is a user-centred platform that streamlines property transactions with centralised case management, automated quoting, and efficient client onboarding. We help agents, panel managers, and solicitors save time, enhance client relationships, and boost referral and conversion rates, providing a competitive edge with faster, simpler transactions. Book a free demo today via our website!
early stageLegal Services
Experience · 8 entries
All (8)
Investments (3)
Founder (3)
2025
Portfolio Leadership
2025
Founded in 2001, Truffle Capital is an independent, European venture capital firm focused on disruptive technologies in IT (FinTech and InsurTech) and Life Sciences (BioTech and MedTech). Truffle Capital aims to support the creation and growth of young innovative companies with the potential to become tomorrow’s market leaders. Chaired by Patrick Kron, alongside the company’s founders and CEOs, Philippe Pouletty and Bernard-Louis Roques, Truffle Capital raised over $1.1 billion and has supported over 75 companies since its creation, in the digital technologies and life sciences sectors. At the end of 2017, Truffle Capital successfully completed the first close of its two new institutional funds, Truffle Financial Innovation Fund and Truffle BioMedTech Fund, as well as the first close of a fund dedicated to the French Reserve Fund (« Fonds de Réserve pour les Retraites » or « FRF »). On December 2019, Truffle Capital successfully raises nearly €400 million for new Venture Capital funds: Truffle BioMedTech Fund and Truffle Financial Innovation Fund.
2024
Investor & Board of Advisors
Aug 2024
HerculesAI is a generative AI company that brings the power of large language models inside the security perimeter of enterprises. Its powerful operating and orchestration platform, Hercules, enables enterprises to quickly create, deploy, and run generative AI apps without compromising security standards. These apps can augment knowledge workers in any domain, resulting in higher revenue, improved profitability, and enhanced worker satisfaction. To learn more visit https://www.hercules.ai
2023
Investor & Board of Advisors
Mar 2023
Lindus is an Accountable Research Organization, engineered to give biotech and pharmaceutical sponsors confidence and control to generate clinical data on time and on budget. In the last 3 years, Lindus has executed over 45 full-scope trials across cardiometabolic, respiratory, psychiatry, dermatology, womens health, and diagnostics. Behind each study is an integrated model spanning feasibility, central enrollment infrastructure, and flexible site models. Trials run on Citrus™, an AI-native trial operating system, and are governed by performance-based contracts with milestone-based payments. 82% of Lindus executed trials completed enrollment on or ahead of our proposed timeline. The company is backed by Dr. Bob Langer, Peter Thiel, and Dr. Tim Garnett.
Co-Founder & Board of Directors - Spinout
Jan 2023
The University of Cambridge is one of the worlds foremost research universities. The University is made up of 31 Colleges and over 150 departments, faculties, schools and other institutions. Its mission is to contribute to society through the pursuit of education, learning, and research at the highest international levels of excellence​.
General Partner
2023
271.vc is a deep tech investing and advisory firm. We take hard technology from the lab to scaled adoption. We invest pre-seed and seed, partnering with founders from invention through growth, working hands-on across go-to-market, capital strategy, and M&A. For select later-stage companies, we advise on partnerships, carve-outs, and exits. We know what its like to be in the founders shoes, weve built and exited companies ourselves. Applied AI, bio & medtech, accelerated computing, biomanufacturing, energy & climate.
Show all 8 entries ↓
Investment activity
2021–2024 · 3 investments
202112023120241
Recent (last 2 years)Earlier